Alzheimer’s disease (AD) is the leading cause of dementia worldwide and is poised to become a major public health crisis. To date, there are few single treatments, pharmaceutical or otherwise, that can help with this degenerative condition.

The Institute for Functional Medicine, in collaboration with Dale Bredesen, MD, and MPI Cognition, presents a two-day CME program this September, with an exciting new approach to the treatment of early stage AD and mild cognitive impairment (MCI). During this program, attendees will learn a multi-pronged treatment strategy for these patients. Using a systems biology approach, attendees will learn to assess patients for MCI and early AD, stratify them based on the likely causes of their dysfunction, and apply a multimodal protocol to individualize treatments for each patient that address the appropriate underlying causes. In this way, you can arrest cognitive decline and in many cases even reverse it.